pharma · Osteoarthritis, Knee · Eosinophilic esophagitis · EPRX
EUPRAXIA PHARMACEUTICALS
EUPRAXIA PHARMACEUTICALS INC.
EUPRAXIA PHARMACEUTICALS is a pharma organization headquartered in Victoria, CA. It trades on NYSE under ticker EPRX. Primary therapeutic focus areas include Osteoarthritis, Knee, Eosinophilic esophagitis, Eosinophilic E
Victoria, CA HQ
2012 Founded
52 Employees
Public company Type
EPRX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Victoria, CA
- Founded
- 2012
- Employees
- 52
- Programs
- 4
- Drugs
- 1
- Patents
- 3
TETRACOSACTIDE , EP-104GI
Phase 2 · small molecule · Eosinophilic esophagitis
TETRACOSACTIDE , EP-104GI for Eosinophilic esophagitis is a Phase 2 program (small_molecule) at EUPRAXIA PHARMACEUTICALS INC. with 1 ClinicalTrials.gov record(s).
Internal code EP-104IAR-102
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- EUPRAXIA PHARMACEUTICALS INC.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Eosinophilic esophagitis
- Status
- active
- Trials
- 1